Personalised medicine and patent law: an overview of the patenting of genetic inventions under United States and European law in relation to genetic diagnostic tests
Following the U.S. Supreme Court decisions in Mayo Collaborative Services v. Prometheus Labs. Inc. and Ass'n for Molecular Pathology v. Myriad Genetics, Inc., the future of patentability of genetic material is uncertain. In the U.S., the decision in Myriad which allowed the patenting of cDNA mo...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Florence
European University Institute
2017
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Following the U.S. Supreme Court decisions in Mayo Collaborative Services v. Prometheus Labs. Inc. and Ass'n for Molecular Pathology v. Myriad Genetics, Inc., the future of patentability of genetic material is uncertain. In the U.S., the decision in Myriad which allowed the patenting of cDNA molecules seems to have limited the force of the concerned voices from the genomic research community that had called for substantial limitations on the patenting genetic material based on the argument that these patents seriously inhibit genomic research and prevent broader provision of genetic diagnostic tests to the public. In the EU, and in markets under the EPC, the patentability issue remain unclear due to lack of judicial guidance. This status quo coincides with the ambitions of governments in both sides of the Atlantic for incentivising research and investment in personalised medicine, a field that is dependent on genetic diagnostic tests and promises radical improvement in public healthcare provision, but also potentially lots of profit and tax. In the light of all these, this paper explores social, political and more particularly legal issues surrounding developments in genomic technologies and personalised medicine, and offers an extensive overview of the limits of substantive patent law in the patenting of genetic inventions in the U.S. and Europe. The paper concludes that the approach of the Biotechnology Directive under EU law setting an over-arching industrial applicability requirement for gene patents offers a balanced response to the challenges created by these patents. Other solutions such as widening the scope of compulsory licensing or the experimental use exception, or creating a sui generis gene right are also visited. Finally, new CRISPR technology that might further challenge the existing legal frameworks is briefly introduced |
| Beschreibung: | Award date: 30 September 2017. - Supervisor: Professor Giovanni Sartor, European University Institute |
| Beschreibung: | vi, 114 Seiten 30 cm |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV045248268 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 181024s2017 |||| 00||| eng d | ||
| 035 | |a (DE-599)BVBBV045248268 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-M382 | ||
| 100 | 1 | |a Timocin Cantekin, Zeynep |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Personalised medicine and patent law |b an overview of the patenting of genetic inventions under United States and European law in relation to genetic diagnostic tests |c Zeynep Timocin Cantekin |
| 264 | 1 | |a Florence |b European University Institute |c 2017 | |
| 300 | |a vi, 114 Seiten |c 30 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Award date: 30 September 2017. - Supervisor: Professor Giovanni Sartor, European University Institute | ||
| 520 | |a Following the U.S. Supreme Court decisions in Mayo Collaborative Services v. Prometheus Labs. Inc. and Ass'n for Molecular Pathology v. Myriad Genetics, Inc., the future of patentability of genetic material is uncertain. In the U.S., the decision in Myriad which allowed the patenting of cDNA molecules seems to have limited the force of the concerned voices from the genomic research community that had called for substantial limitations on the patenting genetic material based on the argument that these patents seriously inhibit genomic research and prevent broader provision of genetic diagnostic tests to the public. In the EU, and in markets under the EPC, the patentability issue remain unclear due to lack of judicial guidance. This status quo coincides with the ambitions of governments in both sides of the Atlantic for incentivising research and investment in personalised medicine, a field that is dependent on genetic diagnostic tests and promises radical improvement in public healthcare provision, but also potentially lots of profit and tax. In the light of all these, this paper explores social, political and more particularly legal issues surrounding developments in genomic technologies and personalised medicine, and offers an extensive overview of the limits of substantive patent law in the patenting of genetic inventions in the U.S. and Europe. The paper concludes that the approach of the Biotechnology Directive under EU law setting an over-arching industrial applicability requirement for gene patents offers a balanced response to the challenges created by these patents. Other solutions such as widening the scope of compulsory licensing or the experimental use exception, or creating a sui generis gene right are also visited. Finally, new CRISPR technology that might further challenge the existing legal frameworks is briefly introduced | ||
| 650 | 4 | |a Genes / Patents | |
| 650 | 4 | |a Biotechnology / Patents | |
| 650 | 4 | |a Patent laws and legislation / Europe | |
| 650 | 7 | |a Biotechnology |2 fast | |
| 650 | 7 | |a Genes |2 fast | |
| 650 | 7 | |a Patent laws and legislation |2 fast | |
| 651 | 7 | |a Europe |2 fast | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |o 10.2870/106056 |
| 856 | 4 | 1 | |u http://hdl.handle.net/1814/49748 |x European University Institute |z kostenfrei |3 Volltext |
| 912 | |a ebook | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-030636339 | ||
Datensatz im Suchindex
| _version_ | 1804178989915308032 |
|---|---|
| any_adam_object | |
| author | Timocin Cantekin, Zeynep |
| author_facet | Timocin Cantekin, Zeynep |
| author_role | aut |
| author_sort | Timocin Cantekin, Zeynep |
| author_variant | c z t cz czt |
| building | Verbundindex |
| bvnumber | BV045248268 |
| collection | ebook |
| ctrlnum | (DE-599)BVBBV045248268 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03252nam a2200373 c 4500</leader><controlfield tag="001">BV045248268</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">181024s2017 |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV045248268</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-M382</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Timocin Cantekin, Zeynep</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Personalised medicine and patent law</subfield><subfield code="b">an overview of the patenting of genetic inventions under United States and European law in relation to genetic diagnostic tests</subfield><subfield code="c">Zeynep Timocin Cantekin</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Florence</subfield><subfield code="b">European University Institute</subfield><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">vi, 114 Seiten</subfield><subfield code="c">30 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Award date: 30 September 2017. - Supervisor: Professor Giovanni Sartor, European University Institute</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Following the U.S. Supreme Court decisions in Mayo Collaborative Services v. Prometheus Labs. Inc. and Ass'n for Molecular Pathology v. Myriad Genetics, Inc., the future of patentability of genetic material is uncertain. In the U.S., the decision in Myriad which allowed the patenting of cDNA molecules seems to have limited the force of the concerned voices from the genomic research community that had called for substantial limitations on the patenting genetic material based on the argument that these patents seriously inhibit genomic research and prevent broader provision of genetic diagnostic tests to the public. In the EU, and in markets under the EPC, the patentability issue remain unclear due to lack of judicial guidance. This status quo coincides with the ambitions of governments in both sides of the Atlantic for incentivising research and investment in personalised medicine, a field that is dependent on genetic diagnostic tests and promises radical improvement in public healthcare provision, but also potentially lots of profit and tax. In the light of all these, this paper explores social, political and more particularly legal issues surrounding developments in genomic technologies and personalised medicine, and offers an extensive overview of the limits of substantive patent law in the patenting of genetic inventions in the U.S. and Europe. The paper concludes that the approach of the Biotechnology Directive under EU law setting an over-arching industrial applicability requirement for gene patents offers a balanced response to the challenges created by these patents. Other solutions such as widening the scope of compulsory licensing or the experimental use exception, or creating a sui generis gene right are also visited. Finally, new CRISPR technology that might further challenge the existing legal frameworks is briefly introduced</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Genes / Patents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biotechnology / Patents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Patent laws and legislation / Europe</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biotechnology</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Genes</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Patent laws and legislation</subfield><subfield code="2">fast</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">Europe</subfield><subfield code="2">fast</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="o">10.2870/106056</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">http://hdl.handle.net/1814/49748</subfield><subfield code="x">European University Institute</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ebook</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-030636339</subfield></datafield></record></collection> |
| geographic | Europe fast |
| geographic_facet | Europe |
| id | DE-604.BV045248268 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:12:44Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-030636339 |
| open_access_boolean | 1 |
| owner | DE-M382 |
| owner_facet | DE-M382 |
| physical | vi, 114 Seiten 30 cm |
| psigel | ebook |
| publishDate | 2017 |
| publishDateSearch | 2017 |
| publishDateSort | 2017 |
| publisher | European University Institute |
| record_format | marc |
| spelling | Timocin Cantekin, Zeynep Verfasser aut Personalised medicine and patent law an overview of the patenting of genetic inventions under United States and European law in relation to genetic diagnostic tests Zeynep Timocin Cantekin Florence European University Institute 2017 vi, 114 Seiten 30 cm txt rdacontent n rdamedia nc rdacarrier Award date: 30 September 2017. - Supervisor: Professor Giovanni Sartor, European University Institute Following the U.S. Supreme Court decisions in Mayo Collaborative Services v. Prometheus Labs. Inc. and Ass'n for Molecular Pathology v. Myriad Genetics, Inc., the future of patentability of genetic material is uncertain. In the U.S., the decision in Myriad which allowed the patenting of cDNA molecules seems to have limited the force of the concerned voices from the genomic research community that had called for substantial limitations on the patenting genetic material based on the argument that these patents seriously inhibit genomic research and prevent broader provision of genetic diagnostic tests to the public. In the EU, and in markets under the EPC, the patentability issue remain unclear due to lack of judicial guidance. This status quo coincides with the ambitions of governments in both sides of the Atlantic for incentivising research and investment in personalised medicine, a field that is dependent on genetic diagnostic tests and promises radical improvement in public healthcare provision, but also potentially lots of profit and tax. In the light of all these, this paper explores social, political and more particularly legal issues surrounding developments in genomic technologies and personalised medicine, and offers an extensive overview of the limits of substantive patent law in the patenting of genetic inventions in the U.S. and Europe. The paper concludes that the approach of the Biotechnology Directive under EU law setting an over-arching industrial applicability requirement for gene patents offers a balanced response to the challenges created by these patents. Other solutions such as widening the scope of compulsory licensing or the experimental use exception, or creating a sui generis gene right are also visited. Finally, new CRISPR technology that might further challenge the existing legal frameworks is briefly introduced Genes / Patents Biotechnology / Patents Patent laws and legislation / Europe Biotechnology fast Genes fast Patent laws and legislation fast Europe fast Erscheint auch als Online-Ausgabe 10.2870/106056 http://hdl.handle.net/1814/49748 European University Institute kostenfrei Volltext |
| spellingShingle | Timocin Cantekin, Zeynep Personalised medicine and patent law an overview of the patenting of genetic inventions under United States and European law in relation to genetic diagnostic tests Genes / Patents Biotechnology / Patents Patent laws and legislation / Europe Biotechnology fast Genes fast Patent laws and legislation fast |
| title | Personalised medicine and patent law an overview of the patenting of genetic inventions under United States and European law in relation to genetic diagnostic tests |
| title_auth | Personalised medicine and patent law an overview of the patenting of genetic inventions under United States and European law in relation to genetic diagnostic tests |
| title_exact_search | Personalised medicine and patent law an overview of the patenting of genetic inventions under United States and European law in relation to genetic diagnostic tests |
| title_full | Personalised medicine and patent law an overview of the patenting of genetic inventions under United States and European law in relation to genetic diagnostic tests Zeynep Timocin Cantekin |
| title_fullStr | Personalised medicine and patent law an overview of the patenting of genetic inventions under United States and European law in relation to genetic diagnostic tests Zeynep Timocin Cantekin |
| title_full_unstemmed | Personalised medicine and patent law an overview of the patenting of genetic inventions under United States and European law in relation to genetic diagnostic tests Zeynep Timocin Cantekin |
| title_short | Personalised medicine and patent law |
| title_sort | personalised medicine and patent law an overview of the patenting of genetic inventions under united states and european law in relation to genetic diagnostic tests |
| title_sub | an overview of the patenting of genetic inventions under United States and European law in relation to genetic diagnostic tests |
| topic | Genes / Patents Biotechnology / Patents Patent laws and legislation / Europe Biotechnology fast Genes fast Patent laws and legislation fast |
| topic_facet | Genes / Patents Biotechnology / Patents Patent laws and legislation / Europe Biotechnology Genes Patent laws and legislation Europe |
| url | http://hdl.handle.net/1814/49748 |
| work_keys_str_mv | AT timocincantekinzeynep personalisedmedicineandpatentlawanoverviewofthepatentingofgeneticinventionsunderunitedstatesandeuropeanlawinrelationtogeneticdiagnostictests |